Request Appointment
22 S Greene StBaltimore, MD 21201
Fax+1 410-328-6896
Overview of Dr. Kocoglu
Dr. Mehmet Kocoglu is an oncologist in Baltimore, MD and is affiliated with University of Maryland Medical Center. He received his medical degree from Hacettepe University FOM and has been in practice 30 years. He is one of 110 doctors at University of Maryland Medical Center who specialize in Oncology. He has more than 40 publications and over 500 citings.
Education & Training
Yale-New Haven Medical CenterFellowship, Hematology and Medical Oncology, 2010 - 2013
University of Arkansas for Medical Sciences (UAMS) College of MedicineResidency, Internal Medicine, 2003 - 2006- University of Arkansas for Medical Sciences (UAMS) College of MedicineResidency, Internal Medicine, 1999 - 1999
Hacettepe University FOMClass of 1996
Certifications & Licensure
MD State Medical License 2014 - 2026
CT State Medical License 2010 - 2015
AR State Medical License 2006 - 2011
American Board of Internal Medicine Hematology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EHR Suite, Epic Systems Corporation, 2016-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2016-2017
Publications & Presentations
PubMed
- Arlocabtagene autoleucel-a GPRC5D-targeted CAR T-cell therapy in heavily pretreated relapsed/refractory multiple myeloma.Susan Bal, Myo Htut, Omar Nadeem, Larry D Anderson Jr, Tara Gregory
Blood. 2026-06-02 - Real-World Experience With a ZUMA-1 Cohort 4 Adopted Approach to CRS and ICANS in CAR-T Recipients.Chiranjeevi Sainatham, Olga Goloubeva, Philip Margiotta, Hanan Alharthy, Imari Patel
European Journal of Haematology. 2026-05-12 - Efficacy of stem cell boost (SCB) for chimeric antigen receptor-T cell therapy (CAR-T)-related hematologic toxicity in patients with relapsed/refractory multiple myelo...Cindy Varga, Myra Robinson, James A Davis, Hamza Hashmi, Thomas G Martin
Blood Cancer Journal. 2026-03-20
Abstracts/Posters
- Increased Cortical Glycolysis Following CD19 CART Therapy: A Radiographic Surrogate for an Altered Blood-Brain BarrierMehmet Hakan Kocoglu, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) after CD19-Directed Chimeric Antigen Receptor T-Cell Therapy (CAR-T) for Large B-Cell Lymphoma: Predicti...Mehmet Hakan Kocoglu, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
